Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment
- Friday, April 10, 2020, 7:03
- Finance
- Add a comment
SONGDO, South Korea and SAN FRANCISCO, April 9, 2020 /PRNewswire/ — Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir’s SARS-CoV-2…
About the Author
adminasapcorp has written 41558 stories on this site.